The evolution and future of integrated evidence planning

Area of Science:

• Pharmaceutical Sciences
• Health Informatics
• Biotechnology

Background:

• Integrated Evidence Planning (IEP) is crucial for aligning drug development with regulatory, clinical, and market demands.
• The pharmaceutical industry faces increasing complexity in evidence generation and market access strategies.

Purpose of the Study:

• To examine the role and application of IEP across the drug development lifecycle.
• To explore the impact of advanced technologies, including AI/ML and generative AI, on IEP.
• To discuss challenges and best practices for successful IEP implementation.

Main Methods:

• Review of IEP principles and applications in drug development.
• Analysis of integrated analytical techniques (descriptive, ML, causal inference).
• Discussion of technological advancements (AI/ML, NLP, generative AI) and real-world evidence.

Main Results:

• IEP optimizes drug development and market access by ensuring evidence aligns with diverse needs.
• Advanced technologies, particularly generative AI, are poised to revolutionize IEP, improving decision-making and patient access.
• Real-world evidence plays an evolving role, necessitating IEP to be a dynamic and iterative process.

Conclusions:

• Successful IEP implementation requires addressing organizational barriers, data accessibility, and specialized tools.
• Generative AI offers transformative potential for on-demand insights and data access within IEP.
• Strong leadership, stakeholder alignment, and resource optimization are key to maximizing IEP benefits.